Jessica L Hurtubise1, Wendie N Marks1, Don A Davies1, Jillian K Catton1, Glen B Baker2, John G Howland3. 1. Department of Physiology, University of Saskatchewan, GB33, Health Sciences Building, 107 Wiggins Rd, Saskatoon, SK, S7N 5E5, Canada. 2. Department of Psychiatry (NRU), University of Alberta, Edmonton, AB, T6G 2B7, Canada. 3. Department of Physiology, University of Saskatchewan, GB33, Health Sciences Building, 107 Wiggins Rd, Saskatoon, SK, S7N 5E5, Canada. john.howland@usask.ca.
Abstract
RATIONALE: The cognitive symptoms observed in schizophrenia are not consistently alleviated by conventional antipsychotics. Following a recent pilot study, sodium nitroprusside (SNP) has been identified as a promising adjunct treatment to reduce the working memory impairments experienced by schizophrenia patients. OBJECTIVE: The present experiments were designed to explore the effects of SNP on the highly translatable trial-unique, delayed nonmatching-to-location (TUNL) task in rats with and without acute MK-801 treatment. METHODS: SNP (0.5, 1.0, 2.0, 4.0, and 5.0 mg/kg) and MK-801 (0.05, 0.075, and 0.1 mg/kg) were acutely administered to rats trained on the TUNL task. RESULTS: Acute MK-801 treatment impaired TUNL task accuracy. Administration of SNP (2.0 mg/kg) with MK-801 (0.1 mg/kg) failed to rescue performance on TUNL. SNP (5.0 mg/kg) administration nearly 4 h prior to MK-801 (0.05 mg/kg) treatment had no preventative effect on performance impairments. SNP (2.0 mg/kg) improved performance on a subset of trials. CONCLUSION: These results suggest that SNP may possess intrinsic cognitive-enhancing properties but is unable to block the effects of acute MK-801 treatment on the TUNL task. These results are inconsistent with the effectiveness of SNP as an adjunct therapy for working memory impairments in schizophrenia patients. Future studies in rodents that assess SNP as an adjunct therapy will be valuable in understanding the mechanisms underlying the effectiveness of SNP as a treatment for schizophrenia.
RATIONALE: The cognitive symptoms observed in schizophrenia are not consistently alleviated by conventional antipsychotics. Following a recent pilot study, sodium nitroprusside (SNP) has been identified as a promising adjunct treatment to reduce the working memory impairments experienced by schizophreniapatients. OBJECTIVE: The present experiments were designed to explore the effects of SNP on the highly translatable trial-unique, delayed nonmatching-to-location (TUNL) task in rats with and without acute MK-801 treatment. METHODS: SNP (0.5, 1.0, 2.0, 4.0, and 5.0 mg/kg) and MK-801 (0.05, 0.075, and 0.1 mg/kg) were acutely administered to rats trained on the TUNL task. RESULTS: Acute MK-801 treatment impaired TUNL task accuracy. Administration of SNP (2.0 mg/kg) with MK-801 (0.1 mg/kg) failed to rescue performance on TUNL. SNP (5.0 mg/kg) administration nearly 4 h prior to MK-801 (0.05 mg/kg) treatment had no preventative effect on performance impairments. SNP (2.0 mg/kg) improved performance on a subset of trials. CONCLUSION: These results suggest that SNP may possess intrinsic cognitive-enhancing properties but is unable to block the effects of acute MK-801 treatment on the TUNL task. These results are inconsistent with the effectiveness of SNP as an adjunct therapy for working memory impairments in schizophreniapatients. Future studies in rodents that assess SNP as an adjunct therapy will be valuable in understanding the mechanisms underlying the effectiveness of SNP as a treatment for schizophrenia.
Authors: Joao Paulo Maia-de-Oliveira; Joao Abrao; Paulo R Evora; Antonio W Zuardi; Jose A S Crippa; Paulo Belmonte-de-Abreu; Glen B Baker; Serdar M Dursun; Jaime E C Hallak Journal: J Clin Psychopharmacol Date: 2015-02 Impact factor: 3.153
Authors: Joao Paulo Maia-de-Oliveira; Bruno Lobão-Soares; Glen B Baker; Serdar M Dursun; Jaime E C Hallak Journal: Schizophr Res Date: 2014-09-13 Impact factor: 4.939
Authors: Haralahalli D Bhagyavathi; Urvakhsh Meherwan Mehta; Jagadisha Thirthalli; C Naveen Kumar; J Keshav Kumar; D K Subbakrishna; Bangalore N Gangadhar Journal: Psychiatry Res Date: 2015-07-16 Impact factor: 3.222
Authors: Wilhelmina A M Vingerhoets; Oswald J N Bloemen; Geor Bakker; Therese A M J van Amelsvoort Journal: Front Psychiatry Date: 2013-12-04 Impact factor: 4.157
Authors: Ian R Winship; Serdar M Dursun; Glen B Baker; Priscila A Balista; Ludmyla Kandratavicius; Joao Paulo Maia-de-Oliveira; Jaime Hallak; John G Howland Journal: Can J Psychiatry Date: 2018-05-09 Impact factor: 4.356
Authors: Michael D Anderson; John W Paylor; Gavin A Scott; Quentin Greba; Ian R Winship; John G Howland Journal: Learn Mem Date: 2020-05-15 Impact factor: 2.460